Financial insights of VNRX

MyFinsight

For the quarter ending 2025-09-30, VNRX made $627,277 in revenue. -$5,387,443 in net income. Net profit margin of -858.86%.

Unit: Dollar

Income Statement	2025-09-30	2025-06-30	2025-03-31	2024-12-31
Total revenues	627,277	406,688	246,385	181,596
Research and development	2,285,907	2,720,207	2,607,444	3,608,453.5
General and administrative	2,483,793	2,940,754	2,243,362	2,193,829
Sales and marketing	958,567	1,043,534	917,299	1,462,235.5
Total operating expenses	5,728,267	6,704,495	5,768,105	7,264,518
Operating loss	-5,100,990	-6,297,807	-5,521,720	-7,082,922
Grant income	232,184	75,991	121,566	5,996.667
Gain (loss) on disposal of fixed assets	0	330	-	-19
Interest income	160	160	158	4,483.5
Interest expense	143,800	123,356	96,669	84,862
Amortization of debt discount	729,630	325,305	-	-
Gain on change in fair value of derivative liability	304,443	418,681	-	342,826.583
Gain (loss) on change in fair value of warrant liability	27,842	-62,764	20,038	-
Total other income (expenses)	-308,801	-16,263	45,093	268,425.75
Net loss	-5,409,791	-6,314,070	-5,476,627	-
Net loss attributable to non-controlling interest	-	29,992	-52,868	-158,864.5
Net loss attributable to volitionrx limited stockholders	-	-6,284,078	-5,423,759	-6,814,496.25
Foreign currency translation adjustments	22,348	-575,996	-	-
Net loss attributable to volitionrx limited stockholders	-	-	-	-7,080,380.5
Net comprehensive loss	-5,387,443	-6,890,066	-	-

- basic and diluted	108,213,068	102,654,095	96,536,052	21,632,793
Net loss per share - basic and diluted attributable to volitionrx limited stockholders	-0.05	-0.06	-0.06	-0.078